Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
The cross-sectional study supports the role that the
Read Article
Discussions regarding family planning, contraception, and pregnancy should be approached at each clinic visit to ensure providers understand patients’ personal goals. These conversations have the potential to decrease the risk of unplanned pregnancies. However, rheumatologists may need to manage
Read Article
Links:
Significant disparities exist in pregnancy outcomes in women with systemic lupus erythematosus (SLE), with previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women with SLE.
Read Article
Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.
When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do our activity measures truly represent disease? Are there some measures best suited to different
Read Article
Links:
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
Vaccination Cut Long COVID Risk for Rheum Patients Patients with
Links:
Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.
Data
Read ArticleA prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.
Read Article
Links:
Links:
The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.
Read ArticleWhat may seem like a prudent approach to treatment of inflammatory bowel disease (IBD) in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from tumor necrosis factor (TNF) inhibitors.
Read Article
Two large RA registries have shown that pregnancy outcomes in rheumatoid arthritis (RA) patients is more related to RA disease activity rather than treatments use to control RA.
Analysis of the Swedish Rheumatology Quality Register abd the Danish clinical quality register (DANBIO)
Read Article
Links:
